论文部分内容阅读
目的探讨静丙球蛋白对小儿重症手足口病治疗的临床效果。方法 150例小儿重症手足口病患儿为研究对象,采取随机数表法分为A、B、C组,每组50例。三组均给予利巴韦林(IVIG)抗病毒药物及相关治疗,A组给予IVIG 1 g/(kg·d),B组给予IVIG 0.5 g/(kg·d),C组给予200 mg/(kg·d),观察患儿用药后惊跳消退时间、皮疹消退时间、发热缓解时间及治疗时间。结果 A、B两组较C组总有效率显著较高(P<0.05),A、B两组相比差异无统计学意义(P>0.05)。与C组相比,A、B两组的惊跳消退时间、皮疹消退时间、发热缓解时间、治疗时间显著较低,差异有统计学意义(P<0.05);A、B两组数据相比,差异无统计学意义(P>0.05)。A组的不良反应发生情况显著高于B、C两组,差异有统计学意义(P<0.05)。结论中度剂量与大剂量静丙球蛋白治疗小儿重症手足口病的疗效相当,可选择中度剂量静丙球蛋白治疗小儿重症手足口病。
Objective To investigate the clinical effect of intravenous immunoglobulin on the treatment of severe hand-foot-mouth disease in children. Methods A total of 150 children with severe HFMD were enrolled in this study. The patients were divided into groups A, B and C by random number table, 50 in each group. Three groups were given ribavirin (IVIG) antiviral drugs and related treatment. Group A received IVIG 1 g / (kg · d), Group B received IVIG 0.5 g / (kg · d), Group C received 200 mg / (kg · d), observed children with asthma subsided time, rash subsided time, fever relief time and treatment time. Results The total effective rate of group A and group B was significantly higher than that of group C (P <0.05). There was no significant difference between group A and group B (P> 0.05). Compared with the C group, A, B two groups of asthma extinction time, rash subsided time, fever remission time, treatment time was significantly lower, the difference was statistically significant (P <0.05); A, B two groups of data compared , The difference was not statistically significant (P> 0.05). Adverse reactions in group A were significantly higher than those in groups B and C (P <0.05). Conclusion Moderate dose and high dose of gavageol treatment of pediatric severe hand, foot and mouth disease, the effect is similar, you can choose moderate dose of gavagen in children with severe hand-foot-mouth disease.